<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40933383</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1554795</StartPage><MedlinePgn>1554795</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1554795</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2025.1554795</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in managing hyperglycemia and reducing cardiovascular (CV) outcomes. However, its effects on arrhythmic, major CV, and microvascular outcomes remain uncertain. This systematic review and meta-analysis aimed to evaluate these outcomes in patients with type 2 diabetes (T2D) treated with semaglutide.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched the PubMed, Embase, and Cochrane databases for eligible randomized controlled trials (RCTs) reported up to November 2024. We performed a meta-analysis via a random-effects model to estimate overall relative risks (RRs) with 95% confidence intervals (CIs) for arrhythmic, major CV, and microvascular outcomes. We conducted subgroup analyses on the basis of different administration types, treatment comparisons, and treatment durations. Additionally, we performed a meta-regression for retinopathy complications on the basis of baseline patient characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">This meta-analysis included 30 RCTs encompassing 32490 patients with T2D. Compared with the controls, semaglutide significantly reduced the incidence of atrial fibrillation (AF) (RR 0.73, 95% CI 0.54 to 0.98), complete atrioventricular (AV) block (RR 0.22, 95% CI 0.06 to 0.80), death from CV causes (RR 0.76, 95% CI 0.58 to 0.98), and revascularization (RR 0.68, 95% CI 0.52 to 0.88). Subgroup analyses revealed that semaglutide (long-term treatment) reduced the risk of AF, supraventricular tachycardia, and complete AV block. Meta-regression analysis revealed that the heterogeneity of retinopathy complications was not associated with baseline patient characteristics.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Semaglutide reduces the risk of AF, complete AV block, death from CV causes, and revascularization in patients with T2D, with long-term treatment showing greater benefits for arrhythmic outcomes.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://www.crd.york.ac.uk/prospero/, identifier CRD42024618146.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wu, Xing, Huang, Zhou, Sun, Yu and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Boxuan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huishan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>53AXN4NNHX</RegistryNumber><NameOfSubstance UI="C000591245">semaglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>62340-29-8</RegistryNumber><NameOfSubstance UI="D004763">Glucagon-Like Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>89750-14-1</RegistryNumber><NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004763" MajorTopicYN="Y">Glucagon-Like Peptides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="Y">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055806" MajorTopicYN="Y">Microvessels</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052216" MajorTopicYN="N" AutoHM="Y">Glucagon-Like Peptide 1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">arrhythmic</Keyword><Keyword MajorTopicYN="N">cardiovascular</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">microvascular</Keyword><Keyword MajorTopicYN="N">semaglutide</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40933383</ArticleId><ArticleId IdType="pmc">PMC12417197</ArticleId><ArticleId IdType="doi">10.3389/fendo.2025.1554795</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen GC, Hukportie DN, Liu YJ, Wang HP, Qin LQ, Fan WD, et al. Microvascular disease, cardiovascular health, and risk of coronary heart disease in type 2 diabetes: A UK biobank study. J Clin Endocrinol Metab. (2024) 109:2335&#x2013;42. doi:&#xa0; 10.1210/clinem/dgae100, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgae100</ArticleId><ArticleId IdType="pubmed">38412317</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx N, M&#xfc;ller-Wieland D, Verket M, Sch&#xfc;tt K. Management of cardiovascular diseases in patients with diabetes: ESC guidelines 2023. Herz. (2024) 49:15&#x2013;8. doi:&#xa0; 10.1007/s00059-023-05218-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-023-05218-x</ArticleId><ArticleId IdType="pubmed">37878038</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. (2024) 47:1873&#x2013;88. doi:&#xa0; 10.2337/dci24-0003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci24-0003</ArticleId><ArticleId IdType="pubmed">38843460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. (2023) 20:463&#x2013;74. doi:&#xa0; 10.1038/s41569-023-00849-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-023-00849-3</ArticleId><ArticleId IdType="pubmed">36977782</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain M, Bain SC, Jeppesen OK, Lingvay I, S&#xf8;rrig R, Treppendahl MB, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. (2020) 22:442&#x2013;51. doi:&#xa0; 10.1111/dom.13955, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13955</ArticleId><ArticleId IdType="pmc">PMC7064975</ArticleId><ArticleId IdType="pubmed">31903692</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, et al. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). Diabetes Obes Metab. (2023) 25:1503&#x2013;11. doi:&#xa0; 10.1111/dom.14998, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14998</ArticleId><ArticleId IdType="pubmed">36722623</ArticleId></ArticleIdList></Reference><Reference><Citation>Linda CM. Glucagon-like peptide-1 receptor agonists: A new frontier in atrial fibrillation treatment. EP Lab Digest. (2025) 1:24&#x2013;6.</Citation></Reference><Reference><Citation>Saglietto A, Falasconi G, Penela D, Francia P, Sau A, Ng FS, et al. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis. Eur J Clin Invest. (2024) 54:e14292. doi:&#xa0; 10.1111/eci.14292, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.14292</ArticleId><ArticleId IdType="pubmed">39058274</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. doi:&#xa0; 10.1136/bmj.n71, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, J&#xfc;ni P, Moher D, Oxman AD, et al. The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. (2011) 343:d5928. doi:&#xa0; 10.1136/bmj.d5928, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. (2015) 45:139&#x2013;45. doi:&#xa0; 10.1016/j.cct.2015.09.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2015.09.002</ArticleId><ArticleId IdType="pmc">PMC4639420</ArticleId><ArticleId IdType="pubmed">26343745</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J&#xf3;dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med. (2016) 375:1834&#x2013;44. doi:&#xa0; 10.1056/NEJMoa1607141, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1607141</ArticleId><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahr&#xe9;n B, Masmiquel L, Kumar H, Sargin M, Karsb&#xf8;l JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. (2017) 5:341&#x2013;54. doi:&#xa0; 10.1016/S2213-8587(17)30092-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(17)30092-X</ArticleId><ArticleId IdType="pubmed">28385659</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroda VR, Bain SC, Cariou B, Piletic M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. (2017) 5:355&#x2013;66. doi:&#xa0; 10.1016/S2213-8587(17)30085-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(17)30085-2</ArticleId><ArticleId IdType="pubmed">28344112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb&#xf8;l JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. (2017) 5:251&#x2013;60. doi:&#xa0; 10.1016/S2213-8587(17)30013-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(17)30013-X</ArticleId><ArticleId IdType="pubmed">28110911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. (2018) 41:258&#x2013;66. doi:&#xa0; 10.2337/dc17-0417, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc17-0417</ArticleId><ArticleId IdType="pubmed">29246950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. (2018) 20:1202&#x2013;12. doi:&#xa0; 10.1111/dom.13218, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13218</ArticleId><ArticleId IdType="pmc">PMC5969242</ArticleId><ArticleId IdType="pubmed">29322610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratley RE, Aroda VR, Lingvay I, L&#xfc;demann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. (2018) 6:275&#x2013;86. doi:&#xa0; 10.1016/S2213-8587(18)30024-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(18)30024-X</ArticleId><ArticleId IdType="pubmed">29397376</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. (2018) 103:2291&#x2013;301. doi:&#xa0; 10.1210/jc.2018-00070, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2018-00070</ArticleId><ArticleId IdType="pmc">PMC5991220</ArticleId><ArticleId IdType="pubmed">29688502</ArticleId></ArticleIdList></Reference><Reference><Citation>Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. (2018) 20:378&#x2013;88. doi:&#xa0; 10.1111/dom.13082, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13082</ArticleId><ArticleId IdType="pmc">PMC5813234</ArticleId><ArticleId IdType="pubmed">28786547</ArticleId></ArticleIdList></Reference><Reference><Citation>Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. (2019) 42:1724&#x2013;32. doi:&#xa0; 10.2337/dc19-0749, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-0749</ArticleId><ArticleId IdType="pubmed">31186300</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med. (2019) 381:841&#x2013;51. doi:&#xa0; 10.1056/NEJMoa1901118, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1901118</ArticleId><ArticleId IdType="pubmed">31185157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. (2019) 7:834&#x2013;44. doi:&#xa0; 10.1016/S2213-8587(19)30311-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(19)30311-0</ArticleId><ArticleId IdType="pubmed">31540867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. (2019) 7:515&#x2013;27. doi:&#xa0; 10.1016/S2213-8587(19)30192-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(19)30192-5</ArticleId><ArticleId IdType="pubmed">31189517</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. (2019) 7:528&#x2013;39. doi:&#xa0; 10.1016/S2213-8587(19)30194-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(19)30194-9</ArticleId><ArticleId IdType="pubmed">31189520</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet (Lond Engl). (2019) 394:39&#x2013;50. doi:&#xa0; 10.1016/S0140-6736(19)31271-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31271-1</ArticleId><ArticleId IdType="pubmed">31186120</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. (2019) 42:2272&#x2013;81. doi:&#xa0; 10.2337/dc19-0883, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-0883</ArticleId><ArticleId IdType="pubmed">31530666</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. (2019) 321:1466&#x2013;80. doi:&#xa0; 10.1001/jama.2019.2942, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.2942</ArticleId><ArticleId IdType="pmc">PMC6484814</ArticleId><ArticleId IdType="pubmed">30903796</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. (2019) 42:2262&#x2013;71. doi:&#xa0; 10.2337/dc19-0898, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-0898</ArticleId><ArticleId IdType="pmc">PMC7364672</ArticleId><ArticleId IdType="pubmed">31530667</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. (2019) 7:356&#x2013;67. doi:&#xa0; 10.1016/S2213-8587(19)30066-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(19)30066-X</ArticleId><ArticleId IdType="pubmed">30833170</ArticleId></ArticleIdList></Reference><Reference><Citation>Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1&#x2013;3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. (2020) 46:100&#x2013;9. doi:&#xa0; 10.1016/j.diabet.2019.101117, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2019.101117</ArticleId><ArticleId IdType="pubmed">31539622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. (2020) 8:392&#x2013;406. doi:&#xa0; 10.1016/S2213-8587(20)30074-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30074-7</ArticleId><ArticleId IdType="pubmed">32333876</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies M, F&#xe6;rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2&#xb7;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. (2021) 397:971&#x2013;84. doi:&#xa0; 10.1016/s0140-6736(21)00213-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00213-0</ArticleId><ArticleId IdType="pubmed">33667417</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xed;as JP, Davies MJ, Rosenstock J, P&#xe9;rez Manghi FC, Fern&#xe1;ndez Land&#xf3; L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. (2021) 385:503&#x2013;15. doi:&#xa0; 10.1056/NEJMoa2107519, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107519</ArticleId><ArticleId IdType="pubmed">34170647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. (2021) 23:404&#x2013;14. doi:&#xa0; 10.1111/dom.14232, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14232</ArticleId><ArticleId IdType="pmc">PMC7839591</ArticleId><ArticleId IdType="pubmed">33074557</ArticleId></ArticleIdList></Reference><Reference><Citation>Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. (2022) 10:418&#x2013;29. doi:&#xa0; 10.1016/s2213-8587(22)00085-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-8587(22)00085-7</ArticleId><ArticleId IdType="pubmed">35468322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellerer M, Kaltoft MS, Lawson J, Nielsen LL, Strojek K, Tabak &#xd6;, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab. (2022) 24:1788&#x2013;99. doi:&#xa0; 10.1111/dom.14765, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14765</ArticleId><ArticleId IdType="pmc">PMC9545869</ArticleId><ArticleId IdType="pubmed">35546450</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse JB, Nordahl Christensen H, Harty BJ, Mitchell J, Soule BP, Zacherle E, et al. Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial. BMJ Open Diabetes Res Care. (2023) 11:e003206. doi:&#xa0; 10.1136/bmjdrc-2022-003206, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2022-003206</ArticleId><ArticleId IdType="pmc">PMC10163526</ArticleId><ArticleId IdType="pubmed">37137527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L, Agesen RM, Bain SC, Fu F, Gabery S, Geng J, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia. (2024) 67:1800&#x2013;16. doi:&#xa0; 10.1007/s00125-024-06133-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06133-4</ArticleId><ArticleId IdType="pmc">PMC11410852</ArticleId><ArticleId IdType="pubmed">38985161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahaffey KW, Tuttle KR, Arici M, Baeres FMM, Bakris G, Charytan DM, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. (2024) 46:1096&#x2014;108. doi:&#xa0; 10.1093/eurheartj/ehae613, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae613</ArticleId><ArticleId IdType="pmc">PMC11931213</ArticleId><ArticleId IdType="pubmed">39211948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Bain SC, Bian F, Chen R, Gabery S, Huang S, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia. (2024) 67:1783&#x2013;99. doi:&#xa0; 10.1007/s00125-024-06142-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06142-3</ArticleId><ArticleId IdType="pmc">PMC11410837</ArticleId><ArticleId IdType="pubmed">38985162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ram&#xed;rez P, Paz-Cruz E, Zambrano-Villacres R, et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. (2024) 11 1398059:1398059. doi:&#xa0; 10.3389/fnut.2024.1398059, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2024.1398059</ArticleId><ArticleId IdType="pmc">PMC11090168</ArticleId><ArticleId IdType="pubmed">38742021</ArticleId></ArticleIdList></Reference><Reference><Citation>Navodnik MP, Jane&#x17e; A, &#x17d;uran I. The effect of additional treatment with empagliflozin or semaglutide on endothelial function and arterial stiffness in subjects with type 1 diabetes mellitus-ENDIS study. Pharmaceutics. (2023) 15:(7). doi:&#xa0; 10.3390/pharmaceutics15071945, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15071945</ArticleId><ArticleId IdType="pmc">PMC10385568</ArticleId><ArticleId IdType="pubmed">37514131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalb&#xf8;ge LS, Christensen M, Madsen MR, Secher T, Endlich N, Drenic V, et al. Nephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease. Biomedicines. (2022) 10:1661. doi:&#xa0; 10.3390/biomedicines10071661, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10071661</ArticleId><ArticleId IdType="pmc">PMC9313388</ArticleId><ArticleId IdType="pubmed">35884965</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Sendo M, Dezaki K, Hira T, Sato T, Nakata M, et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nat Commun. (2018) 9:113. doi:&#xa0; 10.1038/s41467-017-02488-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02488-y</ArticleId><ArticleId IdType="pmc">PMC5760716</ArticleId><ArticleId IdType="pubmed">29317623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. (2022) 182:106320. doi:&#xa0; 10.1016/j.phrs.2022.106320, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106320</ArticleId><ArticleId IdType="pubmed">35738455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HD, Ding L, Liu K, Mi LJ, Zhang AK, Yu FY, et al. Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis. Diabetes Metab Syndr. (2024) 18:103067. doi:&#xa0; 10.1016/j.dsx.2024.103067, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2024.103067</ArticleId><ArticleId IdType="pubmed">38955095</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira Almeida G, Nienk&#xf6;tter TF, Balieiro CCA, Pasqualotto E, Cintra JB, Carvalho HCP, et al. Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. (2024) 24:509&#x2013;21. doi:&#xa0; 10.1007/s40256-024-00647-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-024-00647-3</ArticleId><ArticleId IdType="pubmed">38734847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. (2021) 9:653&#x2013;62. doi:&#xa0; 10.1016/s2213-8587(21)00203-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-8587(21)00203-5</ArticleId><ArticleId IdType="pubmed">34425083</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord. (2022) 22:125. doi:&#xa0; 10.1186/s12902-022-01036-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-022-01036-0</ArticleId><ArticleId IdType="pmc">PMC9097124</ArticleId><ArticleId IdType="pubmed">35546664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Mao Y, Wang H, Liu Y, Huang P. Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Clin Drug Investig. (2022) 42:17&#x2013;28. doi:&#xa0; 10.1007/s40261-021-01110-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-021-01110-w</ArticleId><ArticleId IdType="pubmed">34894326</ArticleId></ArticleIdList></Reference><Reference><Citation>Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. (2024) 30:2058&#x2013;66. doi:&#xa0; 10.1038/s41591-024-03015-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03015-5</ArticleId><ArticleId IdType="pmc">PMC11271413</ArticleId><ArticleId IdType="pubmed">38796653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. (2024) 30:2049&#x2013;57. doi:&#xa0; 10.1038/s41591-024-02996-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02996-7</ArticleId><ArticleId IdType="pmc">PMC11271387</ArticleId><ArticleId IdType="pubmed">38740993</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>